Timing is everything for cancer protein p53
Biologists find that restoring the gene for p53 can slow the spread of advanced lung tumors, but doesn’t help early-stage cancers.
Koch Institute
Slideshow: the Koch Institute transforms East Campus environs
Completion of cancer-research building opens green space for community use and creates vibrant streetscape.
Turning off cancer genes
RNA interference holds much promise as a cancer treatment, but technical challenges remain.
A better way to target tumors
In spite of slow progress toward targeting cancer drugs to individual patients, hope remains.
A new target for cancer drugs
Shutting down an enzyme that responds to DNA damage could boost the effects of traditional chemotherapy.
Cancer’s hiding spots revealed
Discovery that tumor cells can escape from chemotherapy could lead to new treatments that prevent relapse.
New Koch Institute building to open soon
Researchers will start moving into the 365,000-square-foot building next week.
Surprising similarities between human and zebrafish tumors
New finding that tumor cells in both species have too many chromosomes could help pinpoint genes that drive cancer development.
An unexpected twist in cancer metabolism
A cancer-cell quirk could be exploited to develop new drugs that starve tumors.
A pharmacy on the back of a cell
Drugs encapsulated in new MIT nanoparticles can hitch a ride to tumors on the surface of immune-system cells.
MIT’s Koch Institute in strategic partnership with Ortho-McNeil-Janssen Pharmaceuticals
Organizations will collaborate in multiple areas of oncology research and technology development.
Tackling cancer on a new front
New program at MIT’s Koch Institute targets the growing cancer problem in India.
Rapid analysis of DNA damage now possible
Technology offers a new way to test potential cancer drugs, detect effects of hazardous agents in our environment.
Weighing the cell
MIT biological engineers devise a way to measure, for the first time, how single cells accumulate mass.
To starve a tumor
MIT’s Matthew Vander Heiden is part of a new generation of cancer researchers trying to exploit cancer cells’ strange metabolism.